scholarly article | Q13442814 |
P50 | author | Ramon Diaz-Arrastia | Q37370205 |
Sid O'Bryant | Q40018183 | ||
P2093 | author name string | Guanghua Xiao | |
Robert Barber | |||
Rachelle Doody | |||
Joan Reisch | |||
Perrie Adams | |||
Steven Waring | |||
Texas Alzheimer's Research Consortium | |||
Thomas Fairchild | |||
P2860 | cites work | Significance analysis of microarrays applied to the ionizing radiation response | Q24606608 |
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 | ||
Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values | Q30955425 | ||
The role of biomarkers in clinical trials for Alzheimer disease | Q31032781 | ||
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins | Q44917427 | ||
Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. | Q51762261 | ||
P433 | issue | 9 | |
P921 | main subject | Alzheimer's disease | Q11081 |
P304 | page(s) | 1077-1081 | |
P577 | publication date | 2010-09-01 | |
P1433 | published in | Archives of Neurology | Q15766672 |
P1476 | title | A serum protein-based algorithm for the detection of Alzheimer disease | |
P478 | volume | 67 |
Q51760901 | A Decade of Blood Biomarkers for Alzheimer's Disease Research: An Evolving Field, Improving Study Designs, and the Challenge of Replication. |
Q90616563 | A Multiplexed Serologic Test for Diagnosis of Lyme Disease for Point-of-Care Use |
Q91973479 | A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease |
Q64943218 | A Precision Medicine Model for Targeted NSAID Therapy in Alzheimer's Disease. |
Q37085325 | A blood screening test for Alzheimer's disease |
Q35203409 | A blood-based algorithm for the detection of Alzheimer's disease |
Q34341870 | A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: results from the AIBL study |
Q28741766 | A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI |
Q34851404 | A depressive endophenotype of mild cognitive impairment and Alzheimer's disease |
Q48176222 | A depressive endophenotype of poorer cognition among cognitively healthy community-dwelling adults: results from the Western Australia memory study. |
Q37564505 | A double-blind, randomized clinical trial of dietary supplementation on cognitive and immune functioning in healthy older adults |
Q35106556 | A functional polymorphism in the promoter region of microRNA-146a is associated with the risk of Alzheimer disease and the rate of cognitive decline in patients |
Q64085064 | A proteomic signature for dementia with Lewy bodies |
Q53331705 | Alzheimer disease: blood-based biomarkers in AD--a silver lining on the horizon. |
Q36966044 | Alzheimer's disease: are blood and brain markers related? A systematic review |
Q36517459 | An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes |
Q38037149 | Analytical aspects of molecular Alzheimer's disease biomarkers |
Q90415776 | Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine |
Q37248571 | Association Between Cognitive Impairment and Chronic Kidney Disease in Mexican Americans |
Q38592041 | Biomarkers in Sporadic and Familial Alzheimer's Disease |
Q36716970 | Biomarkers of Alzheimer's disease among Mexican Americans. |
Q34442605 | Biomarkers of Alzheimer's disease: from central nervous system to periphery? |
Q36818214 | Biomarkers of basic activities of daily living in Alzheimer's disease. |
Q49165122 | Blood methylomic signatures of presymptomatic dementia in elderly subjects with type 2 diabetes mellitus |
Q26774743 | Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology |
Q60950950 | Blood-Derived Plasma Protein Biomarkers for Alzheimer's Disease in Han Chinese |
Q64108130 | Blood-based molecular biomarkers for Alzheimer's disease |
Q37881948 | Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential |
Q47378944 | Blood-based protein biomarkers for diagnosis of Alzheimer disease |
Q35857246 | Can Genetic Analysis of Putative Blood Alzheimer's Disease Biomarkers Lead to Identification of Susceptibility Loci? |
Q47587631 | Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry |
Q36472899 | Characterization of Mexican Americans with mild cognitive impairment and Alzheimer's disease |
Q33603286 | Cognitive impairment in diabetic patients: Can diabetic control prevent cognitive decline? |
Q24289443 | Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges |
Q42683481 | Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer's pathology. |
Q34394080 | Developing novel blood-based biomarkers for Alzheimer's disease |
Q35106599 | Development and validation of risk index for cognitive decline using blood-derived markers |
Q47142477 | Diagnosis of Alzheimer's disease in Brazil: Supplementary exams. |
Q33867548 | Differences in abundances of cell-signalling proteins in blood reveal novel biomarkers for early detection of clinical Alzheimer's disease |
Q47883557 | Early diagnosis of Alzheimer's disease using infrared spectroscopy of isolated blood samples followed by multivariate analyses. |
Q88341051 | Ethnoracial differences in brain structure change and cognitive change |
Q30996727 | Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline |
Q50999408 | Evolving Relevance of Neuroproteomics in Alzheimer's Disease. |
Q58563809 | Factor structure and measurement invariance of a neuropsychological test battery designed for assessment of cognitive functioning in older Mexican Americans |
Q37431174 | Folic acid supplementation improves cognitive function by reducing the levels of peripheral inflammatory cytokines in elderly Chinese subjects with MCI. |
Q24289435 | Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research |
Q36630566 | How predictive of dementia are peripheral inflammatory markers in the elderly? |
Q56989667 | Identifying Neuroimaging and Proteomic Biomarkers for MCI and AD via the Elastic Net |
Q34875967 | Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel |
Q39211852 | Insulin-like growth factor binding protein-2 interactions with Alzheimer's disease biomarkers |
Q50553594 | Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease. |
Q35099780 | Meta-analysis of peripheral blood apolipoprotein E levels in Alzheimer's disease |
Q35844155 | Metabolome in progression to Alzheimer's disease |
Q37325470 | Microfluidics-based point-of-care test for serodiagnosis of Lyme Disease |
Q35497573 | Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signaling proteome. |
Q40457858 | Molecular markers of amnestic mild cognitive impairment among Mexican Americans. |
Q36926716 | Molecular markers of neuropsychological functioning and Alzheimer's disease |
Q35456265 | Molecular neuropsychology: creation of test-specific blood biomarker algorithms |
Q36695912 | Multiplex assessment of a panel of 16 serum molecules for the differential diagnosis of Alzheimer's disease |
Q51408793 | Multiplexing and multivariate analysis in neurodegeneration. |
Q36836566 | Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain |
Q38093255 | Novel biomarkers for bipolar disorder |
Q34449460 | Oxidative stress, testosterone, and cognition among Caucasian and Mexican-American men with and without Alzheimer's disease |
Q35671802 | Perioperative cognitive decline in the aging population |
Q90568291 | Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need |
Q39620255 | PiB-PET Imaging-Based Serum Proteome Profiles Predict Mild Cognitive Impairment and Alzheimer's Disease |
Q34305083 | Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals |
Q34427001 | Plasma based markers of [11C] PiB-PET brain amyloid burden |
Q36932748 | Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease |
Q38037157 | Plasma biomarkers for Alzheimer's disease: much needed but tough to find |
Q36767124 | Plasma proteomics for the identification of Alzheimer disease |
Q36888445 | Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype |
Q64069554 | Potential two-step proteomic signature for Parkinson's disease: Pilot analysis in the Harvard Biomarkers Study |
Q31063014 | Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. |
Q96110135 | Proteomic profiles of incident mild cognitive impairment and Alzheimer's disease among adults with Down syndrome |
Q95269986 | Proteomic profiles of prevalent mild cognitive impairment and Alzheimer's disease among adults with Down syndrome |
Q28552035 | Random Forests Are Able to Identify Differences in Clotting Dynamics from Kinetic Models of Thrombin Generation |
Q48145375 | Reduced TRPC6 mRNA levels in the blood cells of patients with Alzheimer's disease and mild cognitive impairment |
Q31110973 | Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNI |
Q37079726 | Risk factors for mild cognitive impairment among Mexican Americans |
Q50864602 | Serum Interleukin-10 Levels Correlate with Cerebrospinal Fluid Amyloid Beta Deposition in Alzheimer Disease Patients. |
Q47822179 | Serum Protein-Based Profiles as Novel Biomarkers for the Diagnosis of Alzheimer's Disease. |
Q41903809 | Serum granulocyte colony-stimulating factor and Alzheimer's disease |
Q37342809 | Serum-based protein profiles of Alzheimer's disease and mild cognitive impairment in elderly Hispanics. |
Q64122896 | Shared biological pathways for frailty and cognitive impairment: A systematic review |
Q37642461 | Single-subject anxiety treatment outcome prediction using functional neuroimaging |
Q59811719 | Systematic Analysis and Biomarker Study for Alzheimer's Disease |
Q41661052 | Systems medicine and the integration of bioinformatic tools for the diagnosis of Alzheimer's disease |
Q35082697 | Teaming up for biomarker future. Many problems still hinder the use of biomarkers in clinical practice, but new public-private partnerships could improve the situation |
Q47391588 | Texas Mexican American adult normative studies: Normative data for commonly used clinical neuropsychological measures for English- and Spanish-speakers |
Q98292287 | The Alzheimer's Biomarker Consortium-Down Syndrome: Rationale and methodology |
Q37725833 | The Hachinski ischemic scale and cognition: the influence of ethnicity. |
Q36165011 | The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations |
Q38592265 | The Role of Visinin-Like Protein-1 in the Pathophysiology of Alzheimer's Disease |
Q35446931 | The association between pro-inflammatory cytokines, regional cerebral metabolism, and cognitive complaints following adjuvant chemotherapy for breast cancer |
Q90973905 | The impact of comorbid depression-diabetes on proteomic outcomes among community-dwelling Mexican Americans with mild cognitive impairment |
Q53446502 | Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. |
Q35456060 | Validation of a serum screen for Alzheimer's disease across assay platforms, species, and tissues |
Search more.